ARNA Arena Pharmaceuticals, Inc. Stock Quote

ARNA [NASD]

Index	-	P/E	-	EPS (ttm)	-7.37	Insider Own	0.30%	Shs Outstand	59.78M	Perf Week	-5.27%
Market Cap	3.78B	Forward P/E	-	EPS next Y	-8.34	Insider Trans	-10.38%	Shs Float	56.50M	Perf Month	-9.30%
Income	-422.90M	PEG	-	EPS next Q	-2.20	Inst Own	95.10%	Short Float	5.21%	Perf Quarter	-9.86%
Sales	0.06M	P/S	66385.55	EPS this Y	-196.10%	Inst Trans	0.94%	Short Ratio	7.53	Perf Half Y	-16.68%
Book/sh	18.17	P/B	3.40	EPS next Y	0.80%	ROA	-33.90%	Target Price	96.47	Perf Year	-0.32%
Cash/sh	17.80	P/C	3.48	EPS next 5Y	-	ROE	-36.90%	52W Range	59.55 - 90.19	Perf YTD	-19.48%
Dividend	-	P/FCF	-	EPS past 5Y	-9.90%	ROI	-36.70%	52W High	-31.41%	Beta	0.52
Dividend %	-	Quick Ratio	23.60	Sales past 5Y	-52.60%	Gross Margin	-	52W Low	3.88%	ATR	2.29
Employees	363	Current Ratio	23.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.08	Volatility	4.13% 3.31%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	0.70%	Profit Margin	-	Rel Volume	0.73	Prev Close	62.34
Shortable	Yes	LT Debt/Eq	0.04	Earnings	Aug 05 AMC	Payout	-	Avg Volume	390.85K	Price	61.86
Recom	1.70	SMA20	-6.12%	SMA50	-5.09%	SMA200	-13.39%	Volume	286,959	Change	-0.77%

May-18-21

Initiated

Goldman

Buy

$90

Apr-27-21

Initiated

Citigroup

Buy

$104

Apr-26-21

Resumed

Credit Suisse

Outperform

$102

Nov-10-20

Reiterated

Guggenheim

Buy

$115 → $105

Sep-14-20

Resumed

JP Morgan

Overweight

$71

Jun-29-20

Initiated

H.C. Wainwright

Buy

$90

May-18-20

Initiated

Jefferies

Buy

$62

Mar-31-20

Initiated

Guggenheim

Buy

$95

Mar-26-20

Upgrade

BofA/Merrill

Neutral → Buy

$47 → $56

Jan-31-20

Upgrade

JP Morgan

Neutral → Overweight

$58

Nov-13-19

Initiated

BofA/Merrill

Neutral

$51

Dec-13-18

Initiated

Berenberg

Buy

$55

May-31-18

Initiated

RBC Capital Mkts

Outperform

$65

Mar-21-18

Upgrade

Needham

Hold → Buy

$60

Mar-20-18

Reiterated

JMP Securities

Mkt Outperform

$63 → $79

Jan-18-18

Resumed

Credit Suisse

Outperform

$44

Jan-18-18

Initiated

Credit Suisse

Outperform

$44

Jan-03-18

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-11-17

Reiterated

Citigroup

Buy

$23 → $37

Jul-07-17

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

Jul-29-21 04:05PM	Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5 Business Wire
Jul-28-21 06:58AM	Arena Pharma In-Licenses Aristea's CXCR2 Antagonist For Immune-Mediated Inflammatory Diseases Benzinga
Jul-27-21 04:05PM	Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases Business Wire
Jul-22-21 04:05PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-19-21 08:30AM	Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development Business Wire
Jul-06-21 10:30AM	Hedge Funds Are Dumping Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey
Jun-18-21 04:05PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-15-21 04:20PM	10 Best Stocks to Invest Your $1000 Insider Monkey
Jun-14-21 08:30AM	Steven Schoch Elected to Arena Pharmaceuticals Board of Directors Business Wire
Jun-10-21 10:19AM	Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE Zacks
Jun-09-21 10:03AM	Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel Zacks
08:43AM	Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE) Business Wire
Jun-08-21 08:30AM	Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO) Business Wire
Jun-05-21 03:11AM	This Is Why Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) CEO Compensation Looks Appropriate Simply Wall St.
Jun-04-21 11:31AM	Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report? Zacks
Jun-03-21 08:30AM	Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments Business Wire
May-19-21 05:30PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-17-21 01:55AM	What Type Of Shareholders Make Up Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) Share Registry? Simply Wall St.
May-12-21 08:30AM	Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments Business Wire
May-06-21 10:42AM	Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses Zacks
12:31AM	Arena Pharmaceuticals Inc (ARNA) Q1 2021 Earnings Call Transcript Motley Fool
May-05-21 07:05PM	Arena Pharmaceuticals, Inc. (ARNA) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter Business Wire
02:30PM	Arena Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 04:05PM	Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5 Business Wire
Apr-23-21 10:10AM	Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX Business Wire
Apr-19-21 04:05PM	Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report Business Wire
08:30AM	Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience Business Wire
Apr-16-21 06:35PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-29-21 03:09PM	Is ARNA Stock A Buy or Sell? Insider Monkey
Mar-25-21 11:30AM	Arena Pharmaceuticals, Inc. (ARNA) Down 12.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-19-21 08:30AM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-16-21 08:03AM	3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to Buy Motley Fool
Mar-03-21 12:40PM	Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails Zacks
11:07AM	Return On Capital Employed Overview: Arena Pharmaceuticals Benzinga
Mar-02-21 04:05PM	Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial Business Wire
Feb-24-21 06:54AM	Arena Posts Worse-Than-Feared Quarterly Loss As Sales Disappoint SmarterAnalyst
03:02AM	Arena Pharmaceuticals Inc (ARNA) Q4 2020 Earnings Call Transcript Motley Fool
Feb-23-21 04:41PM	Recap: Arena Pharmaceuticals Q4 Earnings Benzinga
04:05PM	Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter Business Wire
02:30PM	Arena Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:29AM	Arena Pharmaceuticals Earnings Preview Benzinga
Feb-18-21 04:05PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-16-21 04:05PM	Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23 Business Wire
08:30AM	Arena Pharmaceuticals Announces Changes to Board of Directors Business Wire
Feb-11-21 12:15AM	Imagine Holding Arena Pharmaceuticals (NASDAQ:ARNA) Shares While The Price Zoomed 400% Higher Simply Wall St.
Feb-07-21 02:13PM	13 Best Hemp Stocks to Buy Now Insider Monkey
Feb-02-21 09:05AM	Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial Business Wire
Jan-22-21 04:04PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-22-20 04:01PM	Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13 PR Newswire
Dec-18-20 01:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Dec-14-20 07:16PM	Is ARNA A Good Stock To Buy Now? Insider Monkey
Dec-11-20 09:00AM	Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference PR Newswire
Dec-08-20 08:30AM	Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial PR Newswire
Nov-30-20 04:05PM	Arena Pharmaceuticals Announces R&D Leadership Transition Business Wire
Nov-24-20 08:30AM	Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1 PR Newswire
Nov-19-20 05:59PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Nov-13-20 05:25AM	Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Nov-10-20 02:27PM	Here's Why Arena Pharmaceuticals Stock Is Plummeting Today Motley Fool -19.64%
09:40AM	Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data Zacks
05:58AM	Companies Like Arena Pharmaceuticals (NASDAQ:ARNA) Are In A Position To Invest In Growth Simply Wall St.
Nov-09-20 10:00PM	Arena Pharmaceuticals Inc (ARNA) Q3 2020 Earnings Call Transcript Motley Fool
05:07PM	Arena Pharmaceuticals: Q3 Earnings Insights Benzinga
04:05PM	Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis PR Newswire
04:01PM	Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial PR Newswire
02:30PM	Arena Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-20 10:18AM	Earnings Preview for Arena Pharmaceuticals Benzinga
Nov-02-20 08:30AM	Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9 PR Newswire
Oct-28-20 08:30AM	Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company PR Newswire
Oct-27-20 12:30PM	Was The Smart Money Right About Arena Pharmaceuticals, Inc. (ARNA)? Insider Monkey
Oct-20-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Oct-09-20 04:30PM	Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community PR Newswire
Oct-01-20 10:22AM	Analyzing Arena Pharmaceuticals's Unusual Options Activity Benzinga
08:30AM	Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome PR Newswire
Sep-18-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
09:00AM	Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit PR Newswire
Sep-16-20 08:30AM	Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis PR Newswire
Sep-11-20 09:59AM	How Much is Arena Pharmaceuticals' (NASDAQ:ARNA) CEO Getting Paid? Simply Wall St.
Sep-09-20 10:40AM	Hedge Funds Arent Done Buying Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey
Sep-04-20 11:41AM	Stocks To Watch: Arena Pharmaceuticals Sees Relative Strength Rating Rise To 83 Investor's Business Daily
Sep-03-20 04:01PM	Arena Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
Sep-01-20 08:30AM	Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata PR Newswire
Aug-19-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Aug-05-20 04:01PM	Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter PR Newswire
Jul-29-20 04:01PM	Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5 PR Newswire
Jul-17-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jul-13-20 02:33PM	What Kind Of Shareholders Own Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)? Simply Wall St.
Jul-12-20 12:02PM	Did Hedge Funds Make The Right Call On Arena Pharmaceuticals, Inc. (ARNA) ? Insider Monkey
Jun-18-20 04:01PM	Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Jun-15-20 08:30AM	Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors PR Newswire
Jun-08-20 04:30PM	Arena Pharmaceuticals Announces R&D Leadership Transition PR Newswire
01:28PM	Edited Transcript of ARNA earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-03-20 01:13AM	Hedge Funds Arent Done Buying Arena Pharmaceuticals, Inc. (ARNA) Insider Monkey
Jun-02-20 04:23PM	Why Bristol Myers' Success In Ulcerative Colitis Sent Arena Stock Flying Investor's Business Daily +16.22%
Jun-01-20 04:01PM	Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
09:30AM	Moving Average Crossover Alert: Arena Pharmaceuticals Zacks
May-28-20 08:30AM	Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
May-27-20 04:01PM	Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
May-26-20 08:30AM	Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates PR Newswire
May-22-20 04:30PM	Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders PR Newswire

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dallas Jayson Donald Alexander	Director	Jun 15	Sale	66.36	1,223	81,158	7,152	Jun 15 05:27 PM
Schmidt Joan	EVP, General Counsel & Sec	Mar 15	Option Exercise	0.00	12,600	0	19,475	Apr 02 08:10 PM
Aurentz Vincent	Executive VP and CBO	Feb 16	Option Exercise	14.80	2,524	37,354	29,524	Feb 18 09:00 PM
Aurentz Vincent	Executive VP and CBO	Feb 16	Sale	85.00	2,524	214,540	27,000	Feb 18 09:00 PM
Lisicki Robert	EVP, Chief Commercial Officer	Feb 02	Option Exercise	40.95	17,500	716,625	26,941	Feb 04 08:57 PM
Lisicki Robert	EVP, Chief Commercial Officer	Feb 02	Sale	78.87	17,500	1,380,308	9,441	Feb 04 08:57 PM
Munshi Amit	President and CEO	Jan 19	Option Exercise	15.50	50,000	775,000	57,750	Jan 20 09:05 PM
Dallas Jayson Donald Alexander	Director	Jan 19	Sale	80.50	1,327	106,824	5,308	Jan 20 09:06 PM
Munshi Amit	President and CEO	Jan 19	Sale	80.14	50,000	4,006,760	7,750	Jan 20 09:05 PM
Munshi Amit	President and CEO	Jan 15	Option Exercise	15.50	50,000	775,000	57,750	Jan 20 09:05 PM
Munshi Amit	President and CEO	Jan 15	Sale	80.24	50,000	4,011,976	7,750	Jan 20 09:05 PM
Munshi Amit	President and CEO	Jan 12	Sale	75.12	14,877	1,117,569	7,750	Jan 14 08:43 PM
Lisicki Robert	EVP, Chief Commercial Officer	Jan 07	Option Exercise	0.00	12,600	0	12,600	Jan 11 09:19 PM
Aurentz Vincent	Executive VP and CBO	Jan 07	Option Exercise	0.00	18,000	0	27,000	Jan 11 09:18 PM
Munshi Amit	President and CEO	Jan 07	Option Exercise	0.00	23,400	0	31,150	Jan 11 09:17 PM
Dallas Jayson Donald Alexander	Director	Dec 11	Buy	69.31	5	347	6,635	Dec 15 04:07 PM
Dallas Jayson Donald Alexander	Director	Dec 08	Buy	66.25	5	331	6,630	Dec 09 04:03 PM
Munshi Amit	President and CEO	Dec 08	Sale	70.00	6,517	456,198	7,750	Dec 09 04:02 PM
Lisicki Robert	EVP, Chief Commercial Officer	Dec 01	Sale	66.06	3,872	255,786	0	Dec 03 04:02 PM
Lisicki Robert	EVP, Chief Commercial Officer	Nov 25	Option Exercise	0.00	6,300	0	6,300	Nov 30 04:02 PM
Cabell Christopher	EVP, Head of R&D, and CMO	Nov 25	Option Exercise	0.00	2,500	0	2,500	Nov 30 04:01 PM
Munshi Amit	President and CEO	Nov 25	Option Exercise	0.00	11,700	0	19,450	Nov 30 04:00 PM
Aurentz Vincent	Executive VP and CBO	Nov 25	Option Exercise	0.00	9,000	0	9,000	Nov 30 04:00 PM
Munshi Amit	President and CEO	Aug 31	Option Exercise	15.50	50,000	775,000	57,750	Aug 31 08:41 PM
Munshi Amit	President and CEO	Aug 31	Sale	70.10	50,000	3,505,035	7,750	Aug 31 08:41 PM
Munshi Amit	President and CEO	Aug 28	Option Exercise	15.50	50,000	775,000	57,750	Aug 31 08:41 PM
Munshi Amit	President and CEO	Aug 28	Sale	70.00	50,000	3,500,000	7,750	Aug 31 08:41 PM
Nova Tina Susan	Director	Aug 26	Option Exercise	18.13	17,300	313,600	33,876	Aug 28 05:21 PM
Nova Tina Susan	Director	Aug 26	Sale	67.94	17,300	1,175,303	16,576	Aug 28 05:21 PM
Lisicki Robert	EVP, Chief Commercial Officer	Aug 04	Option Exercise	40.95	30,000	1,228,500	30,000	Aug 06 04:38 PM
Lisicki Robert	EVP, Chief Commercial Officer	Aug 04	Sale	63.34	30,000	1,900,345	0	Aug 06 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience